

October 13, 2026

National Stock Exchange of India Limited
Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

Symbol: LALPATHLAB

Scrip Code: 539524

Sub: Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, (“Listing Regulations”) - Update on Acquisition by PathLabs Unifiers Private Limited, a Wholly Owned Subsidiary

Dear Sir/ Madam,

With reference to the captioned subject and in continuation of our earlier intimation dated October 12, 2026, regarding update on further investment by Dr. Lal PathLabs Limited ("the Company") in PathLabs Unifiers Private Limited ("PUPL"), a Wholly Owned Subsidiary of the Company, we wish to inform you that PUPL has acquired the remaining 30% equity stake in Centrapath Labs Private Limited ("CPL"), a Subsidiary of PUPL, on October 13, 2026.

Pursuant to the aforesaid acquisition, CPL has become a Wholly Owned Subsidiary of PUPL.

The disclosure(s) as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, as amended from time to time, is enclosed herewith as “**Annexure – A**”.

We request you to please take the same on record.

Thanking You,

Yours Faithfully,

For Dr. Lal PathLabs Limited

Vinay
Digitally signed
by Vinay Gujral
Date:
2026.10.13
18:34:04
+05'30'

Vinay Gujral
Company Secretary & Compliance Officer
Encl: as above

Annexure-A
DISCLOSURE AS PER REGULATION 30 OF LISTING REGULATIONS READ WITH SEBI CIRCULAR NO. SEBI/HO/CFD/CFD-POD-1/P/CIR/2023/123 DATED JULY 13, 2023:

SN	Particulars	Acquisition of Company
1	Name of the target entity, details in brief such as size, turnover etc.	Centrapath Labs Private Limited ("CPL") Turnover: FY 2026: 20.5 Crores FY 2025: 23.7 Crores FY 2024: 20.8 Crores
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	No, the transaction is not a related party transaction.
3	Industry to which the entity being acquired belongs	Healthcare/ Diagnostics Services
4	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The investment pertains to the acquisition by PathLabs Unifiers Private Limited ("PUPL") of the remaining 30% equity stake in its subsidiary, CPL. Consequently, CPL has become a Wholly Owned Subsidiary of PUPL.
5	Brief details of any governmental or regulatory approvals required for the acquisition	Not Applicable
6	Indicative time period for completion of the acquisition	Completed
7	Consideration - whether cash consideration or share swap or any other form and details of the same	Cash Consideration
8	Cost of acquisition and/or the price at which the shares are acquired	Acquired 30% equity shareholding of CPL at INR 1608.352 per share
9	Percentage of shareholding / control acquired and / or number of shares acquired	CPL has now become a Wholly Owned Subsidiary of the PUPL.
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	CPL was incorporated on July 23, 2019, in Indore, Madhya Pradesh and is engaged in business of providing Healthcare/ Diagnostics Services. Turnover: As mentioned in Clause 1 above